Overview

AIDS 347: IL-6 Blockade in Treated HIV Infection

Status:
Completed
Trial end date:
2017-09-11
Target enrollment:
Participant gender:
Summary
The study is a phase I/II, double-blind, placebo-controlled, randomized cross-over clinical trial of tocilizumab (TCZ) or placebo in HIV-infected subjects receiving antiretroviral therapy with suppressed viral replication and CD4+ T cell count ≥350 and ≤1,000 cells/mm3)
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Case Western Reserve University